tetano
Editor, Senior Moderator
Mol Ther. 2016 Jan 22. doi: 10.1038/mt.2016.23. [Epub ahead of print]
[h=1]H7N9 Live attenuated influenza vaccine is highly immunogenic, prevents virus replication and protects against severe bronchopneumonia in ferrets.[/h] de Jonge J[SUP]1[/SUP], Isakova-Sivak I[SUP]2[/SUP], van Dijken H[SUP]1[/SUP], Spijkers S[SUP]1[/SUP], Mouthaan J[SUP]1[/SUP], de Jong R[SUP]3[/SUP], Smolonogina T[SUP]2[/SUP], Roholl P[SUP]4[/SUP], Rudenko L[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian influenza viruses continue to cross the species barrier and may such a virus become transmissible among humans this would pose a great threat to public health. H7N9 emerged in China in 2013 and has since caused considerable morbidity and mortality. In the absence of a universal influenza vaccine, preparedness includes development of subtype specific vaccines. We here developed and evaluated in ferrets an intranasal live attenuated influenza vaccine (LAIV) against H7N9 based on the A/Leningrad/134/17/57 (H2N2) cold-adapted master donor virus. We demonstrate the LAIV is attenuated and safe in ferrets and induces high haemagglutination and neuraminidase inhibiting and virus neutralizing titers. The antibodies against haemagglutinin were also cross-reactive with divergent H7 strains. To assess efficacy, we used an intratracheal challenge ferret model in which an acute severe viral pneumonia is induced that closely resembles viral pneumonia observed in severe human cases. A single and two-dose strategy provided complete protection against severe pneumonia and prevented virus replication. Only on the microscopic level in the lungs, the protective effect of the two-dose strategy appeared better than the single dose. We observed, however, an increased lymphocytic infiltration after challenge in single-vaccinated animals and hypothesize that this a side effect of the model.Molecular Therapy (2016); doi:10.1038/mt.2016.23.
PMID: 26796670 [PubMed - as supplied by publisher]
[h=1]H7N9 Live attenuated influenza vaccine is highly immunogenic, prevents virus replication and protects against severe bronchopneumonia in ferrets.[/h] de Jonge J[SUP]1[/SUP], Isakova-Sivak I[SUP]2[/SUP], van Dijken H[SUP]1[/SUP], Spijkers S[SUP]1[/SUP], Mouthaan J[SUP]1[/SUP], de Jong R[SUP]3[/SUP], Smolonogina T[SUP]2[/SUP], Roholl P[SUP]4[/SUP], Rudenko L[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian influenza viruses continue to cross the species barrier and may such a virus become transmissible among humans this would pose a great threat to public health. H7N9 emerged in China in 2013 and has since caused considerable morbidity and mortality. In the absence of a universal influenza vaccine, preparedness includes development of subtype specific vaccines. We here developed and evaluated in ferrets an intranasal live attenuated influenza vaccine (LAIV) against H7N9 based on the A/Leningrad/134/17/57 (H2N2) cold-adapted master donor virus. We demonstrate the LAIV is attenuated and safe in ferrets and induces high haemagglutination and neuraminidase inhibiting and virus neutralizing titers. The antibodies against haemagglutinin were also cross-reactive with divergent H7 strains. To assess efficacy, we used an intratracheal challenge ferret model in which an acute severe viral pneumonia is induced that closely resembles viral pneumonia observed in severe human cases. A single and two-dose strategy provided complete protection against severe pneumonia and prevented virus replication. Only on the microscopic level in the lungs, the protective effect of the two-dose strategy appeared better than the single dose. We observed, however, an increased lymphocytic infiltration after challenge in single-vaccinated animals and hypothesize that this a side effect of the model.Molecular Therapy (2016); doi:10.1038/mt.2016.23.
PMID: 26796670 [PubMed - as supplied by publisher]